

Davide Campana

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4605317/publications.pdf>

Version: 2024-02-01

134
papers

3,945
citations

117453

34
h-index

133063

59
g-index

137
all docs

137
docs citations

137
times ranked

4035
citing authors

#	ARTICLE	IF	CITATIONS
1	Metastatic and Locally Advanced Pancreatic Endocrine Carcinomas: Analysis of Factors Associated With Disease Progression. <i>Journal of Clinical Oncology</i> , 2011, 29, 2372-2377.	0.8	261
2	Comparison between ⁶⁸ Ga-DOTA-NOC and ¹⁸ F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 1431-1438.	3.3	254
3	⁶⁸ Ga-DOTANOC PET/CT Clinical Impact in Patients with Neuroendocrine Tumors. <i>Journal of Nuclear Medicine</i> , 2010, 51, 669-673.	2.8	227
4	Chromogranin A: Is It a Useful Marker of Neuroendocrine Tumors?. <i>Journal of Clinical Oncology</i> , 2007, 25, 1967-1973.	0.8	211
5	Endocrine pancreatic tumors: factors correlated with survival. <i>Annals of Oncology</i> , 2005, 16, 1806-1810.	0.6	179
6	Standardized Uptake Values of ⁶⁸ Ga-DOTANOC PET: A Promising Prognostic Tool in Neuroendocrine Tumors. <i>Journal of Nuclear Medicine</i> , 2010, 51, 353-359.	2.8	161
7	⁶⁸ Ga-labelled peptides for diagnosis of gastroenteropancreatic NET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 52-60.	3.3	112
8	⁶⁸ Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 722-727.	3.3	107
9	Real-World Study of Everolimus in Advanced Progressive Neuroendocrine Tumors. <i>Oncologist</i> , 2014, 19, 966-974.	1.9	84
10	Warm Water or Oil-Assisted Colonoscopy: Toward Simpler Examinations?. <i>American Journal of Gastroenterology</i> , 2008, 103, 581-587.	0.2	81
11	Prognostic Value of ⁶⁸ Ga-DOTANOC PET/CT SUV _{max} in Patients with Neuroendocrine Tumors of the Pancreas. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1843-1848.	2.8	78
12	Prognostic factors in ectopic Cushing's syndrome due to neuroendocrine tumors: a multicenter study. <i>European Journal of Endocrinology</i> , 2017, 176, 453-461.	1.9	66
13	Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data from a large prospective and retrospective Italian epidemiological study: the NET management study. <i>Journal of Endocrinological Investigation</i> , 2012, 35, 817-23.	1.8	64
14	Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs. <i>Endocrine-Related Cancer</i> , 2008, 15, 337-342.	1.6	62
15	Pancreatic Endocrine Tumors Less Than 4 cm in Diameter. <i>Pancreas</i> , 2010, 39, 825-828.	0.5	62
16	Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx). <i>Annals of Oncology</i> , 2018, 29, viii467-viii468.	0.6	61
17	Assessment of the quality of life in chronic pancreatitis using Sf-12 and EORTC Qlq-C30 questionnaires. <i>Digestive and Liver Disease</i> , 2007, 39, 1077-1086.	0.4	60
18	Correlation between MGMT promoter methylation and response to temozolomide-based therapy in neuroendocrine neoplasms: an observational retrospective multicenter study. <i>Endocrine</i> , 2018, 60, 490-498.	1.1	59

#	ARTICLE	IF	CITATIONS
19	Risk Factors for Disease Progression in Advanced Jejunoileal Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2012, 96, 32-40.	1.2	55
20	Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues. <i>Gastroenterology</i> , 2018, 155, 479-489.e7.	0.6	54
21	Everolimus in Pancreatic Neuroendocrine Carcinomas G3. <i>Pancreas</i> , 2017, 46, 302-305.	0.5	53
22	Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 1197-1205.	3.3	50
23	Chromogranin A: From Laboratory to Clinical Aspects of Patients with Neuroendocrine Tumors. <i>International Journal of Endocrinology</i> , 2018, 2018, 1-12.	0.6	49
24	Advanced Digestive Neuroendocrine Tumors. <i>Pancreas</i> , 2014, 43, 212-218.	0.5	46
25	Role of 18F-dopa PET/CT imaging in the management of patients with 111In-pentetreotide negative GEP tumours. <i>Nuclear Medicine Communications</i> , 2007, 28, 473-477.	0.5	45
26	Morphological Factors Related to Nodal Metastases in Neuroendocrine Tumors of the Appendix. <i>Annals of Surgery</i> , 2020, 271, 527-533.	2.1	44
27	The Role of mTOR in Neuroendocrine Tumors: Future Cornerstone of a Winning Strategy?. <i>International Journal of Molecular Sciences</i> , 2018, 19, 747.	1.8	42
28	Endocrine Tumors of the Ileum: Factors Correlated with Survival. <i>Neuroendocrinology</i> , 2006, 83, 380-386.	1.2	41
29	Clinical management of patients with gastric neuroendocrine neoplasms associated with chronic atrophic gastritis: a retrospective, multicentre study. <i>Endocrine</i> , 2016, 51, 131-139.	1.1	40
30	Sporadic Small (≤20mm) Nonfunctioning Pancreatic Neuroendocrine Neoplasm: is the Risk of Malignancy Negligible When Adopting a More Conservative Strategy? A Systematic Review and Meta-analysis. <i>Annals of Surgical Oncology</i> , 2017, 24, 2603-2610.	0.7	39
31	Heterogeneity of Duodenal Neuroendocrine Tumors: An Italian Multi-center Experience. <i>Annals of Surgical Oncology</i> , 2018, 25, 3200-3206.	0.7	39
32	Are There Prognostic Factors Related to Recurrence in Pancreatic Endocrine Tumors?. <i>Pancreatology</i> , 2010, 10, 33-38.	0.5	38
33	PET/CT with 68Gallium-DOTA-peptides in NET: An overview. <i>European Journal of Radiology</i> , 2011, 80, e116-e119.	1.2	38
34	Serum leptin, but not adiponectin and receptor for advanced glycation end products, is able to distinguish autoimmune pancreatitis from both chronic pancreatitis and pancreatic neoplasms. <i>Scandinavian Journal of Gastroenterology</i> , 2010, 45, 93-99.	0.6	34
35	Is 68Ga-DOTA-NOC PET/CT indicated in patients with clinical, biochemical or radiological suspicion of neuroendocrine tumour?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 1278-1283.	3.3	34
36	Patient-reported outcomes in subjects with neuroendocrine tumors of the pancreas. <i>World Journal of Gastroenterology</i> , 2009, 15, 5067.	1.4	33

#	ARTICLE	IF	CITATIONS
37	Tumour type and size are prognostic factors in gastric neuroendocrine neoplasia: A multicentre retrospective study. <i>Digestive and Liver Disease</i> , 2019, 51, 1456-1460.	0.4	32
38	Nonconventional Doses of Somatostatin Analogs in Patients With Progressing Well-Differentiated Neuroendocrine Tumor. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 194-200.	1.8	32
39	The functioning side of the pancreas: a review on insulinomas. <i>Journal of Endocrinological Investigation</i> , 2020, 43, 139-148.	1.8	32
40	Risk factors of type 1 gastric neuroendocrine neoplasia in patients with chronic atrophic gastritis. A retrospective, multicentre study. <i>Endocrine</i> , 2017, 56, 633-638.	1.1	30
41	Quality of life in chronic pancreatitis. <i>World Journal of Gastroenterology</i> , 2006, 12, 6249.	1.4	29
42	Fecal calprotectin and elastase 1 determinations in patients with pancreatic diseases: a possible link between pancreatic insufficiency and intestinal inflammation. <i>Journal of Gastroenterology</i> , 2007, 42, 754-760.	2.3	28
43	Risk and Protective Factors for Small Intestine Neuroendocrine Tumors: A Prospective Case-Control Study. <i>Neuroendocrinology</i> , 2016, 103, 531-537.	1.2	28
44	Biliary stone disease in patients receiving somatostatin analogs for neuroendocrine neoplasms. A retrospective observational study. <i>Digestive and Liver Disease</i> , 2019, 51, 689-694.	0.4	27
45	Biliary Stone Disease in Patients with Neuroendocrine Tumors Treated with Somatostatin Analogs: A Multicenter Study. <i>Oncologist</i> , 2020, 25, 259-265.	1.9	27
46	Landscape and Future Perspectives of Immunotherapy in Neuroendocrine Neoplasia. <i>Cancers</i> , 2020, 12, 832.	1.7	27
47	Plasma acylated ghrelin levels are higher in patients with chronic atrophic gastritis. <i>Clinical Endocrinology</i> , 2007, 67, 761-766.	1.2	26
48	Chronic asymptomatic pancreatic hyperenzymemia is a benign condition in only half of the cases: A prospective study. <i>Scandinavian Journal of Gastroenterology</i> , 2009, 44, 888-893.	0.6	25
49	The role of lymph node ratio in recurrence after curative surgery for pancreatic endocrine tumours. <i>Pancreatology</i> , 2013, 13, 589-593.	0.5	25
50	Validation of the 2010 WHO classification and a new prognostic proposal: A single centre retrospective study of well-differentiated pancreatic neuroendocrine tumours. <i>Pancreatology</i> , 2016, 16, 403-410.	0.5	24
51	Clinico-pathological features, treatments and survival of malignant insulinomas: a multicenter study. <i>European Journal of Endocrinology</i> , 2020, 182, 439-446.	1.9	24
52	Adult coeliac disease diagnosed by endoscopic biopsies in the duodenal bulb. <i>European Journal of Gastroenterology and Hepatology</i> , 2005, 17, 1413-1415.	0.8	22
53	⁶⁸ Ga-DOTA-NOC PET/CT Detects Somatostatin Receptors Expression in von Hippel-Lindau Cerebellar Disease. <i>Clinical Nuclear Medicine</i> , 2011, 36, 64-65.	0.7	21
54	Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors. <i>JAMA Network Open</i> , 2022, 5, e220290.	2.8	21

#	ARTICLE	IF	CITATIONS
55	Treatment of Zollinger-Ellison Syndrome. <i>World Journal of Gastroenterology</i> , 2005, 11, 5423.	1.4	20
56	Large Cell Neuroendocrine Carcinoma of the Lung: Current Understanding and Challenges. <i>Journal of Clinical Medicine</i> , 2022, 11, 1461.	1.0	20
57	Value of Both WHO and TNM Classification Systems for Patients with Pancreatic Endocrine Tumors: Results of a Single-Center Series. <i>World Journal of Surgery</i> , 2009, 33, 2458-2463.	0.8	19
58	Immunobiology of Thymic Epithelial Tumors: Implications for Immunotherapy with Immune Checkpoint Inhibitors. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9056.	1.8	19
59	Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study. <i>Pancreatology</i> , 2018, 18, 198-203.	0.5	18
60	A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2018, 25, 607-618.	1.6	18
61	Evaluation of Patient-Reported Outcome in Subjects Treated Medically for Acute Pancreatitis: A Follow-Up Study. <i>Pancreatology</i> , 2009, 9, 375-382.	0.5	17
62	Radiolabeled Somatostatin Analogues for Diagnosis and Treatment of Neuroendocrine Tumors. <i>Cancers</i> , 2022, 14, 1055.	1.7	17
63	Treatment of malignant pancreatic neuroendocrine neoplasms: middle-term (2-year) outcomes of a prospective observational multicentre study. <i>Hpb</i> , 2013, 15, 935-943.	0.1	16
64	Is surgery the best treatment for sporadic small (≤2cm) non-functioning pancreatic neuroendocrine tumours? A single centre experience. <i>Pancreatology</i> , 2017, 17, 471-477.	0.5	16
65	Histopathological diagnosis of appendiceal neuroendocrine neoplasms: when to perform a right hemicolectomy? A systematic review and meta-analysis. <i>Endocrine</i> , 2019, 66, 460-466.	1.1	16
66	Pancreatic involvement in systemic sarcoidosis. <i>Digestive and Liver Disease</i> , 2004, 36, 222-227.	0.4	15
67	WHO 2010 classification of pancreatic endocrine tumors. Is the new always better than the old?. <i>Pancreatology</i> , 2014, 14, 539-541.	0.5	15
68	Prognostic impact of tumour burden in stage IV neuroendocrine neoplasia: A comparison between pancreatic and gastrointestinal localizations. <i>Pancreatology</i> , 2019, 19, 1067-1073.	0.5	15
69	Gastro-entero-pancreatic neuroendocrine neoplasia: The rules for non-operative management. <i>Surgical Oncology</i> , 2020, 35, 141-148.	0.8	14
70	Is radical surgery always curative in pancreatic neuroendocrine tumors? A cure model survival analysis. <i>Pancreatology</i> , 2018, 18, 313-317.	0.5	13
71	An Overview on Molecular Characterization of Thymic Tumors: Old and New Targets for Clinical Advances. <i>Pharmaceuticals</i> , 2021, 14, 316.	1.7	13
72	A [68Ga]Ga-DOTANOC PET/CT Radiomic Model for Non-Invasive Prediction of Tumour Grade in Pancreatic Neuroendocrine Tumours. <i>Diagnostics</i> , 2021, 11, 870.	1.3	13

#	ARTICLE	IF	CITATIONS
73	The ELISA Fecal Elastase-1 Polyclonal Assay Reacts With Different Antigens Than Those of the Monoclonal Assay. <i>Pancreas</i> , 2005, 31, 200-201.	0.5	11
74	Treatment of Advanced Gastro-Entero-Pancreatic Neuro-Endocrine Tumors: A Systematic Review and Network Meta-Analysis of Phase III Randomized Controlled Trials. <i>Cancers</i> , 2021, 13, 358.	1.7	11
75	Efficacy and Cost-Effectiveness of Immediate Surgery versus a Wait-and-See Strategy for Sporadic Nonfunctioning T1 Pancreatic Endocrine Neoplasms. <i>Neuroendocrinology</i> , 2015, 101, 25-34.	1.2	10
76	Temozolomide alone or in combination with capecitabine in patients with advanced neuroendocrine neoplasms: an Italian multicenter real-world analysis. <i>Endocrine</i> , 2021, 72, 268-278.	1.1	10
77	⁶⁸ Ga DOTANOC PET/CT Detects Primary Malignant Insulinoma. <i>Clinical Nuclear Medicine</i> , 2015, 40, e132-e133.	0.7	9
78	Incidental diagnosis of very small rectal neuroendocrine neoplasms: when should endoscopic submucosal dissection be performed? A single ENETS centre experience. <i>Endocrine</i> , 2019, 65, 207-212.	1.1	9
79	Role of [¹⁸ F]FDG PET/CT in the management of G1 gastro-entero-pancreatic neuroendocrine tumors. <i>Endocrine</i> , 2022, 76, 484-490.	1.1	8
80	Maffucci Syndrome with Hemangioma of the Liver. <i>Case Reports in Gastroenterology</i> , 2009, 3, 1-4.	0.3	7
81	Acute leukaemia following low dose peptide receptor radionuclide therapy for an intestinal carcinoid. <i>Digestive and Liver Disease</i> , 2010, 42, 457-458.	0.4	7
82	Determination of Mammalian Target of Rapamycin Hyperactivation as Prognostic Factor in Well-Differentiated Neuroendocrine Tumors. <i>Gastroenterology Research and Practice</i> , 2017, 2017, 1-9.	0.7	7
83	Good performance of platinum-based chemotherapy for high-grade gastroenteropancreatic and unknown primary neuroendocrine neoplasms. <i>Journal of Chemotherapy</i> , 2018, 30, 53-58.	0.7	7
84	Factors Related to Long-Term Survival in Patients Affected by Well-Differentiated Endocrine Tumors of the Pancreas. <i>ISRN Surgery</i> , 2012, 2012, 1-5.	1.4	6
85	Disease-free survival as a measure of overall survival in resected pancreatic endocrine neoplasms. <i>Endocrine-Related Cancer</i> , 2020, 27, 275-283.	1.6	6
86	Assessment of the Risk of Nodal Involvement in Rectal Neuroendocrine Neoplasms: The NOVARA Score, a Multicentre Retrospective Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 713.	1.0	6
87	Diagnostic value of tumor M2-pyruvate kinase in neuroendocrine tumors. A comparative study with chromogranin A. <i>Anticancer Research</i> , 2003, 23, 2969-72.	0.5	6
88	Lymph node ratio predicts efficacy of postoperative radiation therapy in nonmetastatic Merkel cell carcinoma: A population-based analysis. <i>Cancer Medicine</i> , 2022, 11, 4204-4213.	1.3	6
89	When Should F-18 FDG PET/CT Be Used Instead of ⁶⁸ Ga-DOTA-Peptides to Investigate Metastatic Neuroendocrine Tumors?. <i>Clinical Nuclear Medicine</i> , 2011, 36, 1109-1111.	0.7	5
90	Therapeutic options in lung neuroendocrine tumors. <i>Anti-Cancer Drugs</i> , 2019, 30, 649-654.	0.7	5

#	ARTICLE	IF	CITATIONS
91	Perioperative Chemotherapy in Poorly Differentiated Neuroendocrine Neoplasia of the Bladder: A Multicenter Analysis. <i>Journal of Clinical Medicine</i> , 2020, 9, 1351.	1.0	5
92	Hyperammonemic encephalopathy during XELOX regimen. Is it capecitabine or oxaliplatin responsible?. <i>Anti-Cancer Drugs</i> , 2020, 31, 1103-1105.	0.7	5
93	Lubrication during colonoscopy: A forgotten factor. <i>Digestive and Liver Disease</i> , 2005, 37, 630-631.	0.4	4
94	Comment on "Current Management and Predictive Factors of Lymph Node Metastasis of Appendix Neuroendocrine Tumors" - A National Study From the French Group of Endocrine Tumors (GTE). <i>Annals of Surgery</i> , 2019, 270, e43-e44.	2.1	4
95	Survival after active surveillance <i>versus</i> upfront surgery for incidental small pancreatic neuroendocrine tumours. <i>British Journal of Surgery</i> , 2022, 109, 733-738.	0.1	4
96	A Meal Stimulation Test in the Diagnosis of Pancreatic Endocrine Tumors in Multiple Endocrine Neoplasia Type 1. <i>Endocrine</i> , 2002, 17, 229-232.	2.2	3
97	Optimal Treatment of Zollinger-Ellison Syndrome and Related Conditions in Elderly Patients. <i>Drugs and Aging</i> , 2003, 20, 1019-1034.	1.3	3
98	Basis for treatment of functioning neuroendocrine tumours. <i>Digestive and Liver Disease</i> , 2004, 36, S35-S41.	0.4	3
99	Should we lose hope in adjuvant therapy for neuroendocrine tumors?" In response to: Adjuvant therapy following resection of gastroenteropancreatic neuroendocrine tumors provides no recurrence or survival benefit. <i>Journal of Surgical Oncology</i> , 2020, 122, 570-571.	0.8	3
100	Peptide receptor radionuclide therapy for GEP-NET: consolidated knowledge and innovative applications. <i>Clinical and Translational Imaging</i> , 2021, 9, 423-438.	1.1	3
101	Multimodal Strategy in Localized Merkel Cell Carcinoma: Where Are We and Where Are We Heading?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10629.	1.8	3
102	Patient-reported outcomes in patients with endocrine tumors of the ileum. <i>European Journal of Gastroenterology and Hepatology</i> , 2009, 22, 1.	0.8	3
103	The 3-Dimensional-Computed Tomography Texture Is Useful to Predict Pancreatic Neuroendocrine Tumor Grading. <i>Pancreas</i> , 2021, 50, 1392-1399.	0.5	3
104	Duodenal Gastric Metaplasia and Duodenal Neuroendocrine Neoplasms: More Than a Simple Coincidence?. <i>Journal of Clinical Medicine</i> , 2022, 11, 2658.	1.0	3
105	Multiple gastric endocrine tumours and gastrinomas of the duodenum in a patient with ZES MEN 1. <i>Digestive and Liver Disease</i> , 2008, 40, 476.	0.4	2
106	Cutaneous Scapular Lesion in an Elderly Woman. <i>JAMA Oncology</i> , 2019, 5, 1355.	3.4	2
107	⁶⁸ Ga-DOTANOC PET/CT Detects Multifocal Hepatocellular Carcinoma. <i>Clinical Nuclear Medicine</i> , 2019, 44, 238-239.	0.7	2
108	Sedation during colonoscopy and the benefits of lubrication. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 27, 207-208.	1.9	1

#	ARTICLE	IF	CITATIONS
109	Sedation on demand and lubrication during colonoscopy: should we change our minds?. <i>Gastrointestinal Endoscopy</i> , 2008, 68, 1028-1029.	0.5	1
110	Water-related techniques in colonoscopy: the end justifies the means!. <i>Gastrointestinal Endoscopy</i> , 2009, 70, 1287-1289.	0.5	1
111	Warm Water and Oil Assistance in Colonoscopy. <i>Digestive Diseases and Sciences</i> , 2010, 55, 3286-3288.	1.1	1
112	An acute and severe immunodeficiency syndrome due to a pancreatic ACTH-producing tumor. <i>Emergency Care Journal</i> , 2012, 8, 19.	0.2	1
113	Multiple gastrinomas of the duodenum in a patient with sporadic Zollinger-Ellison syndrome. <i>Endocrine</i> , 2013, 44, 815-816.	1.1	1
114	Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence: response to comments by Ezziddin et al.. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 176-177.	3.3	1
115	Assessing safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic (GEP) and thoracic neuroendocrine tumors (NETs): The phase II LOLA trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS4167-TPS4167.	0.8	1
116	Medical treatment of endocrine gastroenteropancreatic tumors. <i>JOP: Journal of the Pancreas</i> , 2006, 7, 145-9.	1.5	1
117	Tumor M2-pyruvate kinase: Is it a new useful marker for neuroendocrine tumors?. <i>Gastroenterology</i> , 2003, 124, A421.	0.6	0
118	Warm water and oil for the difficult colon. <i>Gastrointestinal Endoscopy</i> , 2009, 69, 391.	0.5	0
119	Metastatic 5-mm rectal neuroendocrine carcinoma. <i>Digestive and Liver Disease</i> , 2011, 43, e25.	0.4	0
120	Everolimus for the treatment of advanced pancreatic neuroendocrine tumors. <i>Clinical Investigation</i> , 2012, 2, 1123-1131.	0.0	0
121	Type 3 Gastric Neuroendocrine Neoplasms: Relationship between Tumor Size, Ki67 and Clinical Outcome. <i>Gastroenterology</i> , 2017, 152, S670.	0.6	0
122	Heterogeneity of Type 1 Gastric Neuroendocrine Neoplasms. <i>Gastroenterology</i> , 2017, 152, S669.	0.6	0
123	Therapy for Locoregional Disease: Stomach/Duodenum, Colon/Rectum. , 2018, , 219-234.		0
124	CAPTEM or FOLFIRI as second-line therapy in neuroendocrine carcinomas and exploratory analysis of predictive role of PET imaging and biological markers (SENECA study). <i>Annals of Oncology</i> , 2018, 29, viii477-viii478.	0.6	0
125	Chromogranin A usefulness in small non-functioning pancreatic neuroendocrine tumors surgical management. <i>Surgery</i> , 2019, 166, 952.	1.0	0
126	A cure model survival analysis of patients affected by small intestinal neuroendocrine neoplasms: the Bologna ENETS center experience. <i>Endocrine</i> , 2019, 64, 702-707.	1.1	0

#	ARTICLE	IF	CITATIONS
127	Siblings Diagnosed With Primary Neuroendocrine Tumor of the Left Hepatic Duct. <i>ACG Case Reports Journal</i> , 2019, 6, e00104.	0.2	0
128	Adjuvant chemotherapy in nonmetastatic goblet cell carcinomas: A population-based analysis.. <i>Journal of Clinical Oncology</i> , 2021, 39, e16203-e16203.	0.8	0
129	Large cell neuroendocrine carcinoma of the lung: Prognostic factors to predict clinical outcomes.. <i>Journal of Clinical Oncology</i> , 2021, 39, e20515-e20515.	0.8	0
130	Prophylactic cholecystectomy is not mandatory in patients candidate to the resection for small intestine neuroendocrine neoplasms: a propensity score-matched and cost-minimization analysis. <i>Updates in Surgery</i> , 2021, , 1.	0.9	0
131	New WHO classification for pancreatic endocrine tumors: Is time to leave the previous one?. <i>Journal of Clinical Oncology</i> , 2012, 30, e14647-e14647.	0.8	0
132	Abstract LB-256: Impact of metformin on progression-free survival in diabetic patients with advanced pancreatic neuroendocrine tumors (pNETs) receiving everolimus and/or somatostatin analogues: A sensitivity analysis of the PRIME-NET (pancreatic multicentric, retrospective, italian metformin) study. , 2017, , .		0
133	Effect of intravenous infusion of amino acids on pancreatic secretion. <i>Hepato-Gastroenterology</i> , 2002, 49, 822-4.	0.5	0
134	Total metabolic tumor volume on 18F-fluorodeoxyglucose-positron emission tomography ([18F]-FDG-PET) scan: A potential prognostic factor in extensive-stage small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8574-8574.	0.8	0